Definium Therapeutics (DFTX) Accounts Payables (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Accounts Payables data on file, last reported at $7.1 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 214.24% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 214.24% increase from a year earlier, with the FY2025 full-year figure at $5.3 million, up 166.02% from the prior year.
• Accounts Payables for Q1 2026 stood at $7.1 million, up from $5.3 million in the prior quarter.
• Over the last five years, Accounts Payables for DFTX reached as high as $8.6 million in Q2 2023 and fell as low as $732000.0 in Q2 2022.
• Historically, Accounts Payables has averaged $4.2 million across 5 years, with a median of $3.3 million in 2022.
• Across the five-year window, Accounts Payables surged 1071.72% in 2023 and slumped 72.04% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $2.1 million in 2022, then soared by 95.93% to $4.1 million in 2023, then sank by 51.4% to $2.0 million in 2024, then soared by 166.02% to $5.3 million in 2025, then jumped by 33.29% to $7.1 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $7.1 million in Q1 2026, $5.3 million in Q4 2025, and $8.1 million in Q3 2025.